References of "Osteoporosis International"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailHealth related quality of life in sarcopenia
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Slomian, Justine ULg et al

in Osteoporosis International (2015), 26(S1), 148-149

Detailed reference viewed: 25 (5 ULg)
Full Text
Peer Reviewed
See detailGlucosamine and chondroitin salts in the management of osteoarthritis in Europe
Reginster, Jean-Yves ULg

in Osteoporosis International (2015), 26(S1), 60-61

Detailed reference viewed: 83 (4 ULg)
Full Text
Peer Reviewed
See detailPercentage of women achieving non-osteoporotic BMD T-scores at the lumbar spine (LS) and total hip (TH) during up to 8 years of Denosumab (Dmab) treatment
Ferrari, S; Libanati, C; Lin, CJF et al

in Osteoporosis International (2015), 26(S1), 149-150

Detailed reference viewed: 56 (4 ULg)
Full Text
Peer Reviewed
See detailPrevalence of frailty in nursing home residents according to various diagnostic tools
Buckinx, Fanny ULg; Reginster, Jean-Yves ULg; Dardenne, Nadia ULg et al

in Osteoporosis International (2015), 26(S1), 160-161

Detailed reference viewed: 59 (14 ULg)
Full Text
Peer Reviewed
See detailBaseline characteristics of the Liège hand osteoarthritis cohort (LIHOC)
Neuprez, Audrey ULg; Bruyère, Olivier ULg; Dardenne, Nadia ULg et al

in Osteoporosis International (2015), 26(S1), 167

Detailed reference viewed: 22 (10 ULg)
Full Text
Peer Reviewed
See detailThe position of Strontium ranelate in today's management of osteoporosis
Reginster, Jean-Yves ULg; Brandi, M.L; Cannata-Andia, J. et al

in Osteoporosis International (2015), 26

Osteoporosis accounts for about 3 % of total European health-care spending. The low proportion of costs for the pharmacological prevention of osteoporotic fracture means that it is highly cost saving ... [more ▼]

Osteoporosis accounts for about 3 % of total European health-care spending. The low proportion of costs for the pharmacological prevention of osteoporotic fracture means that it is highly cost saving, especially in patient with severe osteoporosis or patients who cannot take certain osteoporosis medications due to issues of contraindications or tolerability. Following recent regulatory changes, strontium ranelate is now indicated in patients with severe osteoporosis for whom treatment with other osteoporosis treatments is not possible, and without contraindications including uncontrolled hypertension, established, current or past history of ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease. We review here today’s evidence for the safety and efficacy of strontium ranelate. The efficacy of strontium ranelate in patients complying with the new prescribing information (i.e. severe osteoporosis without contraindications) has been explored in a multivariate analysis of clinical trial data, which concluded that the antifracture efficacy of strontiumranelate is maintained in patients with severe osteoporosis without contraindications and also demonstrated how the new target population mitigates risk. Strontium ranelate is therefore an important alternative in today’s management of osteoporosis, with a positive benefit-risk balance, provided that the revised indication and contraindications are followed and cardiovascular risk is monitored. The bone community should be reassured that there remain viable alternatives in patients in whom treatment with other agents is not possible and protection against the debilitating effects of fracture is still feasible in patients with severe osteoporosis. [less ▲]

Detailed reference viewed: 98 (9 ULg)
Full Text
Peer Reviewed
See detailIs there a specific pattern of lean/fat mass ratio in sarcopenic subjects?
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Croisier, Jean-Louis ULg et al

in Osteoporosis International (2015), 26(S1), 145-146

Detailed reference viewed: 37 (6 ULg)
Full Text
Peer Reviewed
See detailHow can we help implementing ESCEO algorithm in real life?
Reginster, Jean-Yves ULg

in Osteoporosis International (2015), 26(S1), 382

Detailed reference viewed: 20 (7 ULg)
Full Text
Peer Reviewed
See detailVitamin D status of schoolchildren in Northern Algeria, seasonal variations and determinants of vitamin D deficiency
Djennane, M; Lebbah, S; Roux, C et al

in Osteoporosis International (2014), 25(5), 1493-502

Summary There are no published data on the vitamin D status of children living in North Africa. In 435 healthy Algerian children 5–15 years old, we found that vitamin D insufficiency (serum 25 ... [more ▼]

Summary There are no published data on the vitamin D status of children living in North Africa. In 435 healthy Algerian children 5–15 years old, we found that vitamin D insufficiency (serum 25-hydroxyvitamin D (25OHD) <50 nmol/L) was frequent, especially in winter. Low vitamin D status was associated with increased parathyroid hormone (PTH) and leg deformation Introduction As there are no published data on the vitamin D status of children living in North Africa, we evaluated the 25OHD concentration of healthy Algerian children at the end of summer and at the end of winter. As secondary objectives, we studied the various determinants of vitamin D status and the PTH-25OHD relationship in these subjects. Methods Four hundred thirty-five children 5–15 years old were examined and had a blood sample in September 2010. Of them, 408 were sampled again in March 2011. Results Median 25OHD concentration in the whole group was 71.4 nmol/L in September and 52.9 nmol/L in March. In September, 58.4, 29.9, and 8.1 % had a 25OHD concentration below 75, 50, and 30 nmol/L respectively. In March, these percentages increased to 65.2, 41.4, and 17.4 % for the 75, 50, and 30 nmol/L threshold, respectively. In multivariate analysis, older age, darker skin phototype, low daily vitamin D and calcium intake, poor socioeconomic status, and short daily sun exposure remained significantly associated with a 25OHD <50 nmol/L at both visits. In 72 (16.6 %) children, genu varum/valgum was present. Compared to the 363 children without leg deformation, they presented more frequently with the risk factors of vitamin D insufficiency. They also had lower 25OHD concentrations and higher PTH and tALP. Serum PTH and 25OHD concentrations were negatively and significantly correlated (r=−0.43; p<0.001) without a 25OHD threshold above which PTH does not decrease anymore. Conclusion Despite a sunny environment, vitamin D insufficiency is frequent in healthy Algerian children. [less ▲]

Detailed reference viewed: 21 (4 ULg)
Full Text
Peer Reviewed
See detailLong-term fracture rates seen with continued ibandronate treatment : pooled analysis of DIVA and MOBILE long-term extension studies
Miller, PD; Recker, RR; Harris, S et al

in Osteoporosis International (2014), 25(1), 349-357

Detailed reference viewed: 53 (4 ULg)
Full Text
Peer Reviewed
See detailPrevalence of vitamin D inadequacy in European women aged over 80 years
Bruyère, Olivier ULg; Slomian, Justine ULg; Beaudart, Charlotte ULg et al

in Osteoporosis International (2014), 25(2), 196

Detailed reference viewed: 19 (5 ULg)
Full Text
Peer Reviewed
See detailWhat does multiplication of tidemarks mean in the ovine femora-tibial joint ?
Pirson, R; Matagne, A; Nisolle, JF et al

in Osteoporosis International (2014), 25(S2), 172

Detailed reference viewed: 29 (5 ULg)
Full Text
Peer Reviewed
See detailEconomic evaluation of an osteoporosis screening campaign: using FRAX as a prescreening tool
Hiligsmann, Mickaël ULg; Ben Sedrine, Wafa ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2014), 25(2), 38-39

Detailed reference viewed: 58 (13 ULg)
Full Text
Peer Reviewed
See detailEight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the freedom extension
Papapoulos, S; Lippuner, K; Roux, C et al

in Osteoporosis International (2014), 25(2), 46-47

Detailed reference viewed: 350 (2 ULg)
Full Text
Peer Reviewed
See detailBiochemical composition of cartilage with naturally occurring defects in the ovine femora-tibial joint
Matagne, A; Clegg, P; Tew, S et al

in Osteoporosis International (2014), 25(S2), 173

Detailed reference viewed: 26 (3 ULg)
Full Text
Peer Reviewed
See detailOdanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial
McClung, MR; Langdahl, B; Papapoulos, S et al

in Osteoporosis International (2014), 25(5), 573-575

Detailed reference viewed: 22 (1 ULg)
Full Text
Peer Reviewed
See detailQuality of life benefits of knee arthroplasty for osteoarthritis
NEUPREZ, Audrey ULg; François, Garance ULg; KURTH, William ULg et al

in Osteoporosis International (2014), 25(2), 40

Detailed reference viewed: 60 (9 ULg)